Company

We build an easily accessible environment
so that many people in the world can use Ybrain's products and services.

The ValuesWe Pursue

Ybrain pursues human happiness and values through brain science.
Through advanced technology, we move up a new era where we can easily and
conveniently pursue Mental Health in our daily life.

Accessible mental health for Everyone Accessible mental health for Everyone

Our mission

We are a group to work for human happiness.
Our mission is to contribute to the world by developing
technology-based solutions that objectively

look at the state of the brain anytime,
anywhere, and maintain a better state
based on brain science, look at the state of the
brain anytime, anywhere,
and maintain a better state
based on brain science,
materials engineering, and computer engineering.

History & Timeline

The market entrance and IPO

Enter the specialized medical market through partnerships with top domestic pharmaceutical companies

The market entrance and IPO

US FDA First-in-Class approval ongoing

The market entrance and IPO

Listing organizer confirmation and Special listing for technology ongoing

Platform commercialization and clinical acceleration

First Global Phase 3 of depression/Mild
dementia, The Phase 2 completion of schizophrenia and game addiction

Platform commercialization and clinical acceleration

Completion of electronic drug home treatment
platform. FDA approval become visible and international guidelines are published

Platform commercialization and clinical acceleration

Development completion of biosignal analysis
AI platform and entered the domestic/Japanese market

R&D Early clinical trial and platform R&D

Clinical trials for depression, mild cognitive impairment, and dementia

Early clinical trial and platform R&D

Commercialization of early Electroceutical product

Early clinical trial and platform R&D

Development completion of biosignal analysis service prototype

  • 2020 - today

    The market entrance and IPO

  • 2017 - 2020

    Platform commercialization and clinical acceleration

  • 2013 - 2017

    Early clinical trial and platform R&D

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9

History & Timeline

  • 2020 - today

  • 2017 - 2020

  • 2013 - 2017

The market entrance and IPO

Enter the specialized medical market through partnerships with top domestic pharmaceutical companies

US FDA First-in-Class approval ongoing

Listing organizer confirmation and Special listing for technology ongoing

Platform commercialization and clinical acceleration

First Global Phase 3 of depression/Mild
dementia, The Phase 2 completion of schizophrenia and game addiction

Completion of electronic drug home
treatment platform. FDA approval become visible and international guidelines are published

Development completion of biosignal
analysis AI platform and entered the domestic/Japanese market

Early clinical trial and platform R&D

Clinical trials for depression, mild cognitive impairment, and dementia

Clinical trials for depression, mild cognitive impairment, and dementia

Development completion of biosignal analysis service prototype

Ybrain has been expanding the business by being
recognized domestically and overseas in the field of brain science.

2021

  • 02

    Appointment of the Brain Science Advisory Committee of the Korea Research Foundation
    by the Ministry of Science and ICT

  • 04

    Sales Licence acquisition from the Ministry of Food and Drug Safety Korea as the
    first depression home treatment in the same field

  • 05

    Nerve function control personal stress suppression electroceutical V1 release

  • 06

    Designation of excellent R&D innovative products by the Ministry of Trade Industry and Energy

  • 06

    Contract of AR/VR biosignal analysis platform project of KOREA ELECTRONICS ASSOCIATION

  • 08

    Hyundai Motor Brain Computer Interface Device Development Project Completion

2020

  • 02

    6.4 billion won in Series-C Funding attraction (accumulated investment of 22.6 billion won))

  • 08

    Neural function control Personal migraine electroceutical V1 and APP service launching

  • 10

    6 major hospitals Confirmatory Clinical Trials success of the depression home
    treatment in the same field electroceutical

  • 12

    Hyundai Motor Brain Computer Interface Device Development Project contract

  • 12

    Depression, ADHD, addiction, stroke electroceutical SCI paper registration

2019

  • 01

    Accumulated 50,000 sessions achievements for the first time in the electroceutical
    platform industry

  • 03

    Start the first Confirmatory Clinical Trials of six major hospitals for home treatment
    for dementia in the same field

  • 07

    Neurofunction control technology electroceutical platform loading

  • 10

    Signing a joint business contract for HwanIn Pharmaceutical, the No. 1 company
    in the Korea psychiatry

  • 12

    Intellectual Property Management Company Certification by the Korean Intellectual
    Property Office

  • 12

    SCI papers registration on clinical and high-performance electroceutical for dementia

2018

  • 07

    Update the web dashboard and APP service linked to the brain function control
    electroceutical platform

  • 07

    Pilot business start of Brain Function Measurement and Analysis Platform
    V3 in Korea and Japan

  • 09

    Confirmatory Clinical Trials starts at six major hospitals in the first for depression
    home treatment in the same field

  • 09

    Electroceutical Platform won the Minister of Trade Industry and Energy Award

  • 11

    The Ministry of Trade Industry and Energy, a neurostimulation electroceutical platform,
    won a contract for the Korea-US International Joint R&D Project

  • 12

    SCI papers registration of Schizophrenia, addiction electroceutical clinical and
    electrode technology

2017

  • 01

    The development completion of hospital-home brain function control electroceutical
    V2 and personal electroceutical V1

  • 04

    Development completion of APP service linked to electroceutical

  • 04

    Development completion of Brain function measurement and analysis technology V2

  • 09

    Clinical expansion of depression (drug combination, elderly home application) and
    dementia (6 months home application) electroceutical

  • 09

    6 billion won Series-B Funding attraction (accumulated investment of 16.2 billion won)

  • 10

    International Electroceutical Safety Guidelines SCI Paper Registration
    (Harvard Medical University Collaboration)

  • 11

    Completion of The Ministry of Trade Industry and Energy, the Korea-France
    International R&D project and innovation performance recognition

  • 12

    Clinical SCI paper registration for schizophrenia electroceutical

2016

  • 05

    Establishment of US subsidiaries and JV for overseas cooperation

  • 06

    Schizophrenia, ADHD, addiction, and sleep clinical trial expansion

  • 10

    Acquisition of Medical device GMP to be necessary for sales and International ISO13485 certification

  • 12

    Completion of Depression electroceutical, 7 Major hospitals, multi-center clinical trials

  • 12

    K-Global 300 company certification

  • 12

    Clinical SCI paper registration of mild cognitive impairment electroceutical

2015

  • 01

    V1 development completion of Brain function measurement and analysis technology

  • 06

    Efficacy demonstration of awareness improvement of mild cognitive impairment, awareness improvement of the general person, and exercise performance improvement

  • 09

    6 billion won in strategic investment attraction (accumulated 10.2 billion won in investment)

  • 10

    The Ministry of Trade Industry and Energy the Korea-France International R&D project contract

2014

  • 02

    Electroceutical V1 development completion for brain function control

  • 02

    GMP certified for clinical use of medical devices

  • 03

    Electroceutical clinical trial start for dementia and mild cognitive impairment in the
    first time in Korea

  • 08

    3.5 billion won Series-A Funding attraction (accumulated investment amounts of 4.2 billion won)

  • 09

    Depression Electroceutical Korea's First at Seven Major Hospitals Multicenter
    Clinical trial start

2013

  • 02

    Establishment of Ybrain : The goal of commercialization of brain science-based
    therapeutic devices to be used anywhere

  • 02

    700 million won Seed Funding attract

Ybrain Team

  • Business Management

    provides the support of financial, legal, planning, and general affairs, etc., to support the stable cruising of Ybrain's products and services, and implements management tasks across the company.

  • Mental Health

    In order to pursue the value of Mental Health, advanced products, implements strategic tasks such as marketing, PR, domestic sales, overseas businesses, etc, so that many patients can benefit.

  • Production license

    is responsible for certification, quality control, and manufacturing tasks so that customers can safely use digital healthcare products and services, and is responsible for more than 10,000 production infrastructures per month.

  • R&D

    is a sector where Wi-brain's core technologies evolve and develop. In detail, R&D plan products and services including clinical, device, platform, and creative labs, develop technology, and analysis.

Our Partners

Ybrain CI

  • Symbol

  • The most notable symbol was designed to feel like the shape of the brain is overlapped with the alphabet y, and the three shapes in the symbol are designated in the order of the brainstem, cerebrum, and cerebellum.

  • Logo Color

  • Among the cool and lively blue colors, the color was designed to balance chroma and brightness to create a more comfortable and calm feeling.

    • RGB

      98 187 221

      Hex

      #62bbdd

      CMYK

      61 13 13 0

    • RGB

      255 255 255

      Hex

      #ffffff

      CMYK

      0 0 0 0

    • RGB

      20 20 20

      Hex

      #141414

      CMYK

      0 0 0 92

    • RGB

      166 166 166

      Hex

      #a6a6a6

      CMYK

      40 32 31 0